Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
February 7th, 2021
5.6K views
This paper describes methods for the generation, drug treatment, and analysis of patient-derived explants for assessing tumor drug responses in a live, patient-relevant, preclinical model system.
Overview
This article details the methodology for using patient-derived explants (PDEs) as a preclinical platform to assess drug responses in human tumors. The PDE approach preserves the three-dimensional architecture and tumor microenvironment, enabling accurate prediction of patient outcomes and facilitating biomarker discovery for drug sensitivity and resistance.
Key Study Components
Area of Science
- Cancer biology
- Preclinical drug testing
- Tumor microenvironment research
Background
- Traditional preclinical models often fail to replicate the complexity of the human tumor microenvironment and intratumoral heterogeneity.
- PDEs maintain the pathological and architectural features of original tumors, providing a more clinically relevant model.
- PDEs have been shown to distinguish between chemosensitive and chemoresistant tumors, correlating with patient responses.
- This platform enables the study of molecular, genetic, and histological features that predict drug responses.
Purpose of Study
- To provide a detailed protocol for the derivation, culture, and analysis of patient-derived tumor explants.
- To demonstrate how PDEs can be used to evaluate drug efficacy and identify predictive biomarkers.
- To highlight the use of multiplexed immunofluorescence and multispectral imaging for spatial profiling of biomarkers.
Methods Used
- Collection and preparation of fresh tumor tissue, including slicing into small fragments.
- Short-term culture of explants on organotypic inserts in a 3D context.
- Drug treatment of explants with appropriate controls.
- Fixation, histological processing, and embedding of explants for analysis.
- Multiplexed immunofluorescence staining and multispectral imaging for spatial biomarker profiling.
- Image analysis involving tissue and cell segmentation, phenotype classification, and quantitative assessment of cell viability and proliferation.
Main Results
- PDEs enable the identification and phenotyping of individual cell populations within both tumor and stromal regions.
- Quantitative analysis of cell death and proliferation is possible following drug treatment.
- Spatial information, such as intercellular distances, can be extracted from stained tissue sections.
- PDEs can distinguish between drug-sensitive and drug-resistant tumor samples, as demonstrated with immunotherapy agents like Nivolumab.
- The platform supports extensive spatial profiling and mass cytometry for high-dimensional biomarker analysis.
Conclusions
- PDEs provide a robust, clinically relevant model for preclinical drug testing and biomarker discovery.
- This methodology allows for accurate prediction of patient responses and supports the development of personalized cancer therapies.
- The combination of 3D culture, multiplexed imaging, and advanced analysis enables comprehensive assessment of drug effects within the tumor microenvironment.
Frequently Asked Questions
What are patient-derived explants (PDEs)?
PDEs are small fragments of human tumor tissue cultured ex vivo, preserving the original tumor architecture and microenvironment for drug testing and biomarker analysis.
How do PDEs improve upon traditional preclinical cancer models?
PDEs maintain the three-dimensional structure and cellular heterogeneity of tumors, providing more accurate predictions of patient drug responses compared to conventional models.
What types of analyses can be performed on PDEs?
Multiplexed immunofluorescence, multispectral imaging, tissue and cell segmentation, phenotype classification, and spatial profiling of biomarkers can all be performed on PDEs.
How are drug responses assessed in PDEs?
Drug responses are evaluated by quantifying cell viability, proliferation, and death within the explants after treatment, using advanced imaging and analysis techniques.
Can PDEs be used to predict immunotherapy outcomes?
Yes, PDEs can help distinguish between tumors sensitive or resistant to immunotherapies, such as immune checkpoint inhibitors, and investigate underlying mechanisms.
What is the significance of spatial profiling in PDE analysis?
Spatial profiling allows researchers to assess the distribution and interaction of different cell types and biomarkers within the tumor microenvironment, providing deeper insights into drug effects.
Are PDEs suitable for biomarker discovery?
Yes, PDEs facilitate the identification of molecular and cellular biomarkers that predict drug response, aiding in patient stratification and personalized therapy development.
Executive Industry Relevance
Patient-derived tumor explants (PDEs) provide a clinically relevant preclinical platform that preserves the tumor microenvironment and intratumoral heterogeneity, directly addressing a major limitation of traditional models. This enables more predictive assessment of drug resistance and sensitivity, supporting translational continuity from discovery to patient stratification. The PDE platform enhances portfolio decision-making by generating actionable, quantitative drug response and biomarker data aligned with clinical outcomes.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses in a human tumor context.
- Supports functional target validation by preserving tumor-stroma interactions.
- Facilitates mechanistic de-risking through direct measurement of drug effects on viable tumor tissue.
- Improves predictive confidence for advancing targets into later-stage development.
Screening & Assay Development
- Provides a validated 3D biological system for compound screening under physiologically relevant conditions.
- Enables quantitative, reproducible assessment of cell viability, proliferation, and death post-treatment.
- Supports assay standardization and scalability for high-content drug evaluation.
- Allows for multiplexed biomarker analysis to inform screening prioritization.
Translational & Preclinical Research
- Aligns preclinical drug response data with clinicopathological parameters for translational biomarker discovery.
- Enables risk-adjusted advancement decisions by predicting patient-specific drug resistance or sensitivity.
- Supports identification of novel interventional strategies to sensitize resistant tumors.
- Facilitates continuity from discovery through preclinical validation using patient-relevant models.
Pipeline & Workflow Integration
PDEs integrate into the discovery-to-preclinical continuum by providing a bridge between in vitro screening and clinical translation, supporting both lead identification and biomarker-driven patient stratification.
- Discovery Biology: Supports hypothesis testing and pathway clarification in a preserved tumor microenvironment.
- Screening: Delivers reproducible, quantitative outputs for compound evaluation in a 3D context.
- Analytics: Enables high-content measurements, including spatial profiling and cell segmentation, to compare drug effects.
- Translational Research: Aligns drug response data with clinical parameters for biomarker validation.
- Enterprise Reuse: Establishes a reusable platform for ongoing drug sensitivity and resistance studies across tumor types.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in drug response assessment.
- Operational Value: Standardizes workflows for tissue processing, imaging, and quantitative analysis.
- Strategic Value: Improves go/no-go decisions and capital efficiency by linking preclinical data to patient outcomes.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of drug candidates based on clinically relevant data.
Implementation Considerations
- Requires expertise in tissue handling, histology, and advanced imaging analysis.
- Demands access to multiplexed immunofluorescence and multispectral imaging infrastructure.
- Necessitates cross-team standardization for sample processing and data interpretation.
- Adaptation may be needed for different tumor types and bespoke culture conditions.
- Short-term culture limits longitudinal studies but enables rapid drug response assessment.
Biopharma FAQs
Why is null hypothesis testing critical in PDE drug response analysis?
Null hypothesis testing in PDE drug response analysis ensures that observed differences in cell viability or biomarker expression are statistically significant, supporting robust target validation and reducing false positives in early discovery.
How does independent variable isolation in explant drug treatment support discovery workflows?
Isolating drug treatment as the independent variable in PDEs allows clear attribution of observed effects to specific compounds, facilitating mechanistic de-risking and reliable comparison across candidate therapies.
What do quantitative dependent variable measurements enable in PDE analysis?
Quantitative measurements of cell death, proliferation, and biomarker expression enable objective assessment of drug efficacy, supporting data-driven advancement and biomarker discovery for patient stratification.
Why are replication requirements important for cross-functional PDE studies?
Replication ensures reproducibility and reliability of drug response data across teams, enabling consistent interpretation and integration into portfolio decision-making and translational research.
What statistical analysis capabilities are needed before implementing PDE-based screening?
Robust statistical analysis, including segmentation accuracy, phenotype classification, and significance testing, is essential to validate findings and support confident progression of drug candidates in the pipeline.
